23:49 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses A method for performing rapid structural analysis of fragmented protein crystals could help guide the development of drugs targeting difficult-to-crystallize proteins. The method involved breaking large imperfect or mosaic protein crystals into...
20:34 , Nov 9, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of N. meningitidis PilE could help identify epitopes for use in developing vaccines to prevent the infection. An atomic model of PilE generated from 1.44 angstrom (Å)-resolution crystal structures and...
07:00 , Jul 14, 2016 |  BC Innovations  |  Tools & Techniques

Cryo-EM a river

Once considered the poor cousin in structural biology, cryo-electron microscopy (cryo-EM) has found new favor in industry, after technical improvements have broken barriers in molecular size and resolution, resulting in floods of data that can...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

A6: Phase II started

Angstrom began an open-label, U.S. Phase II trial to evaluate subcutaneous A6 twice daily in 28-day cycles for 6 cycles in about 20 patients. Angstrom Pharmaceuticals Inc. , San Diego, Calif.   Product: A6  ...
00:23 , Oct 18, 2013 |  BC Extra  |  Financial News

Biodesy raises $15 million in series A, names CEO

Biodesy Inc. (Burlingame, Calif.) raised $15 million in a series A round led by new investor 5AM Ventures. New investors Pfizer Venture Investments and Roche Venture Fund also participated. Additionally, Biodesy named Greg Yap as...
07:00 , Apr 8, 2013 |  BioCentury  |  Finance

Company builder

Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc. 's biggest backer, the firm has now installed a handpicked CEO and new commercial head. The moves suggest any plans for a public exit...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Rib-X, Sanofi deal

Rib-X received a $3 million milestone payment from Sanofi under a July 2011 deal to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 502 subunit to treat drug-resistant Gram-positive and...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

Rib-X, Sanofi deal

Rib-X received a $9 million milestone payment from Sanofi under a deal signed earlier this month to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 50S subunit to treat drug-resistant...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Rib-X, Sanofi deal

Rib-X partnered with Sanofi to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 50S subunit to treat drug-resistant Gram-positive and Gram-negative pathogens. The partners will jointly participate in discovery and...
00:18 , Jul 7, 2011 |  BC Extra  |  Company News

Sanofi, Rib-X in antibiotic deal

Rib-X Pharmaceuticals Inc. (New Haven, Conn.) partnered with Sanofi (Euronext:SAN; NYSE:SNY) to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 50S subunit to treat drug-resistant Gram-positive and Gram-negative pathogens. The...